Hirsutism cost-effectiveness of therapy: Difference between revisions

Jump to navigation Jump to search
(Created page with "__NOTOC__ {{Hirsutism}} {{CMG}} {{AE}} Please help WikiDoc by adding content here. It's easy! Click here to learn about editing. ==Overview==...")
 
No edit summary
 
(6 intermediate revisions by 2 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Hirsutism}}
{{Hirsutism}}
{{CMG}} {{AE}}
{{CMG}}: {{AE}}; {{RHN}}
 
Please help WikiDoc by adding content here.  It's easy!  Click  [[Help:How_to_Edit_a_Page|here]]  to learn about editing.


==Overview==
==Overview==
[[Oral contraceptives]] and [[spironolactone]] are cost-effective treatment options for hirsutism.


==Cost-effectiveness of Therapy==
==Cost-effectiveness of Therapy==
[[Oral contraceptives]], [[finasteride]], [[spironolactone]] and [[cyproterone acetate]] are known to be effective treatments for hirsutism, specially in short term. However in long term , using [[spironolactone]] may lead to a lower Ferriman-Gallwey score comparing to other treatments. Treatment with [[spironolactone]] is also cost-effective.
In general combination of [[spironolactone]] and oral contraceptives in patients who doesn't respond to single therapy is more [[Cost-effectiveness|cost-effective]] comparing to other treatment combinations.<ref name="pmid19807312">{{cite journal |vauthors=Lumachi F, Zulian E, Scaroni C |title=Cost-effective therapy in patients with idiopathic hirsutism |journal=Expert Rev Pharmacoecon Outcomes Res |volume=4 |issue=3 |pages=297–306 |year=2004 |pmid=19807312 |doi=10.1586/14737167.4.3.297 |url=}}</ref>


==References==
==References==
Line 13: Line 15:


[[Category:Needs content]]
[[Category:Needs content]]
[[Category:Endocrine]]
[[Category:Endocrinology]]
[[Category:Integumentary system]]
[[Category:Gynecology]]
[[Category:Dermatology]]
[[Category:Hair-related diseases]]


{{WH}}
{{WH}}
{{WS}}
{{WS}}

Latest revision as of 17:46, 22 September 2017

Hirsutism Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Hirsutism from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

CT

MRI

Echocardiography or Ultrasonography

Treatment

Medical Therapy

Pharmacological therapy
Non-pharmacological therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Hirsutism cost-effectiveness of therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Hirsutism cost-effectiveness of therapy

CDC on Hirsutism cost-effectiveness of therapy

Hirsutism cost-effectiveness of therapy in the news

Blogs on Hirsutism cost-effectiveness of therapy

Directions to Hospitals Treating Hirsutism cost-effectiveness of therapy

Risk calculators and risk factors for Hirsutism cost-effectiveness of therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]: Associate Editor(s)-in-Chief: ; Rasam Hajiannasab M.D.[2]

Overview

Oral contraceptives and spironolactone are cost-effective treatment options for hirsutism.

Cost-effectiveness of Therapy

Oral contraceptives, finasteride, spironolactone and cyproterone acetate are known to be effective treatments for hirsutism, specially in short term. However in long term , using spironolactone may lead to a lower Ferriman-Gallwey score comparing to other treatments. Treatment with spironolactone is also cost-effective.

In general combination of spironolactone and oral contraceptives in patients who doesn't respond to single therapy is more cost-effective comparing to other treatment combinations.[1]

References

  1. Lumachi F, Zulian E, Scaroni C (2004). "Cost-effective therapy in patients with idiopathic hirsutism". Expert Rev Pharmacoecon Outcomes Res. 4 (3): 297–306. doi:10.1586/14737167.4.3.297. PMID 19807312.

Template:WH Template:WS